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Abstract
Aim: We plan to conduct a randomised clinical trial among people likely to witness opioid overdose to compare the educational effectiveness of point-of-
care naloxone distribution with best-available care, by observing participants’ resuscitation skills in a simulated overdose. This mixed methods feasibility
study aims to assess the effectiveness of recruitment and retention strategies and acceptability of study procedures.
Methods: We implemented candidate-driven recruitment strategies with verbal consent and destigmatizing study materials in a family practice,
emergency department, and addictions service. People 16 years of age who are likely to witness overdose were randomized to point-of-care naloxone
distribution or referral to an existing program. We evaluated participant skills as a responder to a simulated overdose 314 days post-recruitment.
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Retention strategies included flexible scheduling, reminders, cash compensation and refreshments. The primary outcome was recruitment and
retention feasibility, defined as the ability to recruit 28 eligible participants in 28 days, with <50% attrition at the outcome simulation. Acceptability of study
procedures and motivations for participation were assessed in a semi-structured interview.
Results: We enrolled 30 participants over 24 days, and retained 21 participants (70%, 95%CI 56.7100). The most common motivation for participation
was a desire to serve the community or loved ones in distress. Participants reported that study procedures were acceptable and that the outcome
simulation provided a supportive and affirming environment.
Conclusion: The planned trial is ready for implementation. Recruitment and retention is feasible and study processes are acceptable for people who are
likely to witness overdose. (Registration: NCT03821649).
Keywords: Feasibility trial, Pilot trial, Randomized control trial, Opioid overdose, Simulation, Resuscitation, Prehospital care, Bystanders, Substance
use, Overdose education and naloxone distribution, Study recruitment, Study retention, Harm reduction, Emergency medicine, Public health, Addiction
medicine
Background
Overdose education and naloxone distribution (OEND) programs
train people who are likely to witness opioid overdose to respond with
effective first aid interventions, including the administration of the
opioid antagonist naloxone. OEND programs are known to reduce
opioid-related deaths and enhance knowledge and opioid overdose
response skills.13
We plan to conduct a randomised clinical trial (RCT) to compare
the effectiveness of a novel overdose response training tool with the
current best-available OEND program. The novel tool includes a brief
training video and naloxone kit designed for implementation and
distribution in clinical settings, while the best-available alternative
consists of referral to a local pharmacy or harm reduction agency for
OEND. The planned trial will recruit participants in emergency
department, family practice and addictions medicine settings and
evaluate the effectiveness of the intervention by observing partic-
ipants’ performance in a simulated overdose emergency.
The planned trial raises a range of feasibility and logistical
challenges. The planned trial aims to recruit participants including
people who are themselves at risk of opioid overdose and anyone who
is likely to witness overdose, and both patients and visitors in the
clinical environment. There is little precedent for trial recruitment in this
population and setting, or for the use of resuscitation simulations as an
outcome assessment tool among people who are likely to witness
opioid overdose.4 Challenges with participant recruitment and
retention are widely reported among studies seeking to enroll people
who use drugs.57 Before conducting a full-scale trial, a feasibility
study was necessary to determine the effectiveness of our recruitment
and retention strategy, and the acceptability of study procedures.
Objectives
The primary objective was to establish if recruitment and retention of
participants was feasible for the planned RCT. The secondary
objectives were to (A) assess the participant recruitment rate in each
recruitment site, (B) compare participant retention rates in the
experimental and control arms, and (C) describe implementation
challenges and opportunities for study process improvements.
Methods
We conducted a mixed methods feasibility study for a proposed
parallel design RCT. We developed, registered, and published a
feasibility study protocol based on Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) guidelines,
adapted to feasibility studies (ClinicalTrials.gov NCT03821649).8,9
The proposed RCT is described in detail elsewhere (ClinicalTrials.gov
NCT04740099), and the feasibility study replicated all of the proposed
RCT procedures, with the exception of the sample size and data
analysis. There were no scientific protocol amendments or deviations.
This report adheres to the CONSORT Extension for Pilot and
Feasibility Studies (Supplement A: Reporting Checklist).10
The study was approved by research ethics boards at St. Michael’s
Hospital (#17-280), Toronto Public Health (#2017-09), and the
University of Toronto (#RIS37212). This study is part of the Surviving
Opioid Overdose with Naloxone Education and Resuscitation
(SOONER) Project, which combines participatory co-design and
RCT methods to design and evaluate a novel OEND kit and reduce the
stigma of opioid use and overdose.9
Participants
Participants were individuals presenting to the St. Michael’s
Hospital Department of Family and Community Medicine,
Addictions Medicine Service (inpatient or ambulatory care clinic),
the Emergency Department, or the hospital-affiliated Inner City
Family Health Team. Individuals were eligible for participation if
they were at least 16 years of age and at elevated risk of opioid
overdose or likely to witness opioid overdose according to criteria
adapted from 2015 American Heart Association Guidelines
(Table 1).11 Participants could be patients, or visitors accompa-
nying a patient. Detailed inclusion and exclusion criteria are
provided elsewhere.9
Recruitment, consent and retention
To reduce selection biases and ensure that all potentially eligible
candidates were made aware of the study, participants were
recruited using a “candidate-driven” strategy. All patients and
visitors presenting to the recruitment settings were given an
information card indicating that a study was underway for people
who take opioids or are in contact with people who take opioids, and
inviting them to join the study if they were interested. Peer workers,
nurses and physicians could also refer candidates to research
personnel. Patients and visitors who expressed interest in
participating were approached by study personnel to explain
procedures and obtain consent. The study used a verbal consent
process supported by written materials. All study materials were
designed based on participatory approaches using plain,
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destigmatizing and supportive language and formatting.12,13 Given
the variability in operations and work processes in the different
recruitment sites, study materials were customized and adapted to
meet the needs of each study site. Customizations were made at
numerous points in the recruitment process, from recruitment card
distribution to the timing of research interactions within the clinical
encounter. For example, in the family medicine setting, cards were
distributed at registration, and participant recruitment usually
occurred after the clinical encounter. In the emergency department,
cards were distributed at a variety of touchpoints in the process of
care based on the patient’s presentation and recruitment occurred
during waiting periods in the clinical encounter.
We implemented a multi-pronged strategy to support participant
retention. Participants were asked to provide telephone, email, and
text message contact details, and contact information for friends,
family, case workers or other members of their social network who
could assist with follow-up. Outcome assessment and follow-up
appointments were scheduled flexibly and with sufficient time to
reschedule if necessary. Study personnel provided multiple follow-
up phone calls, letters and text message reminders. Each
participant was provided a consistent point of contact among study
personnel from enrolment to study completion. Participants
received cash at each study visit to a maximum of CA$75 for
completing all study visits (CA$25/h), transit tokens, food, and
refreshments.9
Randomisation
Participants were assigned to the control or experimental arm a with
1:2 allocation, stratified by site. Study staff developed and imple-
mented the allocation sequence and completed the randomisation
using RedCap software at Unity Health Toronto.14 Since the control
arm follows existing processes of care, we chose unbalanced
allocation to gather additional information about the experimental
arm. Eligible and consenting participants who presented together in
the same clinical encounter (e.g. a patient and visitor) were assigned
to the same study arm to reduce contamination.
Interventions
Participants randomized to the experimental arm received purpose-
designed point-of-care brief overdose first aid training and a
naloxone kit containing two doses of intranasal naloxone (Nar-
canTM, Adapt Pharmaceuticals) with administration instructions.
Study personnel showed participants a video on how to identify a
life-threatening opioid overdose, activate 911, administer intranasal
naloxone, perform chest compressions, reassess, and continue
chest compressions until paramedics arrive. This video and training
materials are embargoed while the trial is underway to minimize
interference with the study itself.
Control arm participants received best-available care including
referral to an existing local OEND program at a harm reduction service
or retail pharmacy, facilitated with a custom-designed referral card. In
the emergency department, this was supplemented with a pre-existing
on-site OEND program delivered by nursing staff.
All participants were scheduled to engage as a responder in a high-
fidelity overdose simulation 3 to 14 days post-recruitment. The
scenario was co-designed and reviewed by the study’s community
advisers who have lived experience with opioid overdose. This
simulation recreated a life-threatening opioid overdose, where a
manikin model was found in an apartment with no apparent signs of
life. The scenario would proceed with a deterioration to cardiac arrest
and death without prompt intervention. Participants were provided
with a simulated naloxone kit equivalent to the one they would have
received through their training. A telephone enabled simulated calls
with a 911 dispatcher. The simulation was video recorded.
Two paramedic assessors with expertise in prehospital care
reviewed all simulation recordings, conducted independent and
blinded assessments of the simulation recordings, and assigned a
global assessment (pass or fail) to each simulation. A lead investigator
adjudicated discrepancies. Assessors scored participant perfor-
mance on first aid skills using a validated checklist modified for
overdose scenarios.15
Staff provided a standardized video briefing prior to the simulation
to orient participants and instruct them to respond as if the situation
were real. The simulation was followed by a structured simulation
debrief.16 Participants completed an interviewer-administered ques-
tionnaire at enrolment and after the simulation to assess knowledge,
confidence and willingness to respond to overdose including the
validated Opioid Overdose Knowledge and Attitudes Scales (OOKS
and OOAS).17 Participants completed a semi-structured interview
concerning their opioid use and overdose experiences, stigma, and
experiences with study recruitment and participation (Supplement B:
Interview Guide). We conducted a thematic analysis of the
participants’ motivations for participation in the study and their study
experiences, particularly in the simulation.18 We incorporated
feedback received from site staff into refinements to the study’s
implementation procedures.
Table 1 – Eligibility criteria.
Eligibility Criteria (individuals were eligible for the trial if they were a patient or visitor at a study recruitment site,
> = 16 years of age, and met any one or more of the criteria below):
N = 30
No (%)
1 Has a history of taking opioids at recognized ‘high doses’ whether by prescription or otherwise,
defined as >100 mg morphine equivalent per day.
10 (33.3)
2 Has required emergency care for opioid overdose previously. 11 (36.7)
3 Is enrolled in an opioid agonist treatment program or has been in the last 6 months,
including methadone or buprenorphine maintenance.
12 (40)
4 Is being released from prison or has been released in the last 7 days, and has a history of non-medical opioid use. 0 (0)
5 Is receiving prescription opioid therapy with risk factors for adverse effects, including relevant comorbidities,
co-prescriptions of benzodiazepines or other sedatives, concomitant ongoing alcohol use,
or high-dose prescription opioid therapy.
16 (53.3)
6 Uses non-medical opioids, injects opioids, or acquires opioids from sources other than a pharmacy or health care setting. 15 (50.0)
7 Lives with or is in frequent contact with others who use opioids and would be eligible for the study. 14 (46.7)
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Participants who reported injection drug use or were close
contacts of people who injected drugs were asked to complete the
OOKS and OOAS again at 3 months following enrolment. Other
studies have used this time interval with similar populations using the
OOKS and OOAS as outcome measures. This visit was included in the
study to permit comparison with the existing literature.19,20
Feasibility outcomes
The primary outcome for this feasibility study was recruitment and
retention feasibility, defined as the ability to recruit approximately 28
eligible participants in 28 recruitment days, and <50% attrition at the
study’s primary outcome assessment at 314 days. We computed
that at least 19 of 28 participants would need to be retained to exclude
retention rates of <50% based on a one-sided 95% confidence
interval for the binomial distribution.9 We set these feasibility
thresholds based on available resources to continue study processes
and complete a timely definitive trial.
Secondary feasibility outcomes included (A) the proportion of
eligible participants who declined or did not consent to participate, and
(B) the proportion of participants who attended the outcome simulation
but did not complete the simulation or withdrew from the study. Tertiary
feasibility outcomes were the acceptability of recruitment, retention
and outcome assessment procedures as reported by study partic-
ipants in a semi-structured interview, or through informal feedback
gathered from participants and site staff.9
Outcomes of the planned trial
The primary outcome of the planned trial is the proportion of
resuscitation failures as observed in the simulation scenario occurring
314 days after randomisation. The secondary outcome was the
proportion of satisfactory performance on each of the eight first aid
skills: (1) recognise the emergency, (2) position the victim, (3) activate
emergency medical services, (4) administer naloxone (prepare
device, administer correctly), (5) hand placement, (6) chest
compressions rate and depth, (7) continue compressions until end
of simulation and (8) order of operations and organisation. The tertiary
outcomes are participants’ scores on the OOKS and OOAS at the time
of the outcome simulation and at 3-months after randomisation.
Outcome data for the planned trial were gathered and recorded to
ensure the feasibility of study processes, but not analysed or reported
in the context of the feasibility study.
Role of the funding source
The project was funded by the Canadian Institutes of Health Research
(CIHR) grant #148817 and the Canadian Research Initiative in Substance
Misuse. The Canadian Centre on Substance Use and Addiction (CCSA)
contributed to project workshops and community engagement. Funders
had no role in study design, implementation or interpretation.
Results
Recruitment and retention
We enrolled 30 participants during 113 h of recruitment activities,
conducted over 24 days between January 28 and May 28, 2019.
Table 1 shows the percent of participants meeting each of the study’s
eligibility criteria. Table 2 provides socio-demographic characteristics
of participants. All participants were included in the feasibility
outcomes analyses.
One individual asked to speak to study staff based on their interest
in the study, but did not meet eligibility criteria. There were no eligible
candidates who discussed the study with research staff but declined to
participate (Fig. 1). On three occasions, individuals presented
together and were recruited and randomized together (two pairs,
one trio).
Table 3 provides opioid use characteristics among the participants
who reported using opioids themselves. The majority of participants
who reported taking non-prescription opioids used fentanyl (90.9%).
The majority of participants who reported taking prescription opioids
used opioids prescribed for opioid agonist therapy (methadone
64.3%). The majority of participants took opioids one or more times per
day (76%).
We retained 21 participants at the outcome simulation, corre-
sponding with a retention rate of 70% (one-sided 95% CI 56.7100).
Table 4 provides participant retention numbers by study site and for
the experimental and control arms of the study. One participant
withdrew from the study after they viewed the briefing video and
simulation room. They indicated that the choice to withdraw was
related to personal discomfort and the appearance of the physical
space. Of the 16 participants who were eligible for the 3-month follow-
up visit, 4 (25%) were retained.
Table 2 – Participant demographics.
Category Overall N = 30
Age (median [IQR]) 40.5 [33.053.2]




Born in Canada no. (%) 25 (83.3)
Self-reported ethnicity/race no. (%)
Blacka 6 (20.0)




Boarding home 3 (10.0)
Group home 12 (40.0)





High School 8 (26.7)
University/College 12 (40.0)
Graduate/Professional 6 (6.7)
Previous first aid, CPR or OEND training 18 (62.1)
Previously witnessed overdose 11 (36.6)
a Categories collapsed to protect small cell sizes. “Black” included
participants who identified as any of “Black  African”, “Black  Carribean”
and “Black  North American”. “Other” includes any participant who chose
“other” as their self-reported ethnicity/race, or who chose any other category
not listed here.
b Categories collapsed to protect small cell sizes. Includes “correctional
facility/jail,” “own home,” “shelter/hostel” and “supportive housing”.
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Acceptability and refinement of procedures
Participants discussed their experience of engaging with the study in
three domains: motivation for participation, study process experi-
ences, and simulation experiences. Each of these domains and the
dominant themes expressed by participants are provided in Table 5.
Participants expressed a wide range of motivators for engaging in
the study. Most commonly, participants expressed that they perceived
overdose response as a helping behaviour and participated to serve
their community or loved ones in distress. Despite the candidate-
driven recruitment, several participants emphasized the importance of
a referring clinician in their decision to participate. Others indicated
that although they chose to participate on the basis of its educational or
altruistic value, the cash compensation helped to support
participation.
Many participants emphasized that the study processes and
study personnel were pleasant and caring, and created a supportive
environment for study participants. Participants indicated that
reminders were helpful and contributed to retention. No participants
indicated that the reminders were inappropriately intrusive or
frequent. One participant raised concerns about a stigmatizing
experience with security personnel while awaiting research staff in
the hospital lobby (Table 5). This experience was managed as an
opportunity for quality improvement and expanding our community
of support for the trial within the hospital. Study staff reached out to
inform hospital security about the study and engage them in the
project’s ongoing implementation. We also implemented an
emotional support and crisis plan for any participants in distress
throughout the study.
In response to questions about their experiences in the simulation,
most participants indicated that they felt that the simulation
established a comfortable and affirming environment to practice
hands-on overdose response skills. In particular, some participants
emphasized that the simulation elicited challenging emotions,
sometimes related to experiences of responding to overdose. These
responses were largely coupled with the assertion that hands-on
experience and real emotions are necessary to build experience,
skills, and self-efficacy (Table 5). Study staff reported that nearly all
participants indicated that they valued the simulation experience and
felt that it built confidence in their overdose response skills.
Fig. 1 – CONSORT feasibility diagram.
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Clinical and administrative personnel offered feedback con-
cerning study processes, leading to quality improvements and
staff education. For example, in one setting staff expressed
concern about distributing materials at registration, asking
patients and visitors if they use opioids or are in frequent contact
with people who use opioids. This prompted an opportunity to
collaboratively engage site staff in the study’s anti-stigma
strategies, and process refinements whereby research personnel
were permitted to approach patients directly to discuss naloxone
distribution.
Data for the planned trial
Data collection and analysis procedures for the simulation, study
interviews and questionnaires were refined through the feasibility
study. A technical problem resulted in 1 unsuccessful simulation
recording and data loss for this participant. Procedure checks were
implemented to prevent this from recurring. All other simulations were
recorded and assessed by two independent reviewers, confirming the
operability of study databases and feasibility of these study
processes. Study interviews and questionnaire data was collected
per-protocol. Data for the outcomes of the planned trial were not
analysed for the feasibility study.
Discussion
Our findings demonstrate that people who use opioids or are likely to
witness overdose can be successfully recruited to a RCT concerning
OEND, and retained to participate in an overdose simulation. Our
findings demonstrate that the recruitment and retention strategy is
adaptable for successful participant engagement in emergency
department, family practice and addictions medicine settings. In
these settings, the recruitment and retention strategy was successful
in recruiting a sample of participants with diverse ethno-racial, gender,
housing and educational backgrounds among a target population of
people who take opioids or are likely to witness opioid overdose.
Insufficient reporting of socio-demographic data is a gap in Canadian
research concerning the opioid crisis.21 The collection of identifiers is
a study strength, and reinforces that our recruitment and retention
strategy serves a population including structurally marginalized
groups. Study participants were predominantly people who take
fentanyl or methadone and who take opioids one or more times per
day. Our recruitment strategy may be less effective for individuals who
take opioids sporadically.
Collaboration with community members in the study design is a
strength that contributed to the success and feasibility of the study.
Table 3 – Opioid use information among participants who use opioids (N = 16).
Participants who take prescription opioids 14
Methadone or buprenorphine (%)a 10 (71.5)
Morphine (%) 4 (28.6)
Othera 3 (21.4)
Participants who take non-prescription opioids 11
Fentanyl (%) 10 (90.9)
Heroin (%) 5 (45.5)
Other (%) 4 (36.4)
Injection opioid use (%) 7 (43.8)
Number of opioids used (%)
1 5 (31.2)
23 8 (50.0)
4 or more 3 (18.8)
Frequency of opioid use Non-prescription Prescription
n = 11 n = 14
n (%) n (%)
Multiple times per day 4 (36.4) 4 (28.6)
Every day or most daysa 3 (27.2) 10 (71.4)
A few times a week 4 (36.4) 0 (0.0)
Rarely or few times a month 0 (0.0) 0 (0.0)
a Categories merged to protect small cell sizes.
Table 4 – Recruitment and retention by study site and randomisation.
Site
Recruited (N = 30)
n(%)
Completed Simulation (N = 21)
n (% of recruited)
Family medicine 12 (40) 10 (83.3)
Addiction service 10 (33.3) 6 (60.0)
Emergency department 8 (26.7) 5 (62.5)
Randomisation
Experimental 20 14 (70.0)
Control 10 7 (70.0)
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Participants indicated that the study procedures and their participation
as a responder in an opioid overdose simulation were broadly
acceptable and safe. These findings are valuable because adverse
experiences in health care and research are common among people
who take drugs. For all staff involved in participant recruitment and
study implementation, we invested in training and aptitudes to redress
the stigma of opioid use and ensure a supportive, affirming, and
positive research experience for participants. These experiences
support the feasibility of the overall study. Feedback from study
participants and site staff have also contributed to process improve-
ments and troubleshooting.
Our findings are aligned with other studies regarding effective
recruitment and retention strategies for research participants who use
opiate drugs.57 Simplified verbal consent processes, multimodal
reminders, and flexible study visit scheduling have also been shown to
support recruitment and retention in other research contexts and
populations.2225 Our findings reinforce existing evidence that cash
incentives can be used to support participants in a non-coercive
manner.26,27Although many of our participants were recruited through
conventional clinician referrals, our candidate-driven recruitment
method is a novel strategy and may reduce selection biases. The
acceptability of study processes reflects the community-based and
participatory approaches used to design and implement this
research.28
Although our recruitment and retention methods may be used in
other settings and marginalized populations, our study occurred in a
well-resourced metropolitan academic setting. Although elements of
our recruitment and retention strategy may be adaptable to a variety of
contexts, our overall findings may not be generalizable to other
settings or populations. The feasibility of our recruitment and retention
strategy, and the acceptability of our study processes cannot
guarantee the overall viability of the planned trial. Only one individual
who expressed interest in discussing the study with recruitment staff
was found to be ineligible, so it is possible that other eligible
Table 5 – Participant experience of study processes representative quotes.
Domain and theme Representative participant quotes
Domain 1: motivation for participation
Helping behaviours and
altruism
 I think that was a good first step for me . . . I will be around people and if I have a relationship and I want to be able to save their
lives.
 there is ways to help others, you know, . . . there’s solutions that, that can be applied to, to change life . . . I get to learn this,
this the skills to help others someday.
 I have friends that do carfentanyl, fentanyl, OD on heroin or any other opioids, I just need to know that I have some of the skills to
be able to apply them to one of my friends, to help?
Clinician referral  What prompted me nothing really it’s just the doctor asked me if I wanted to participate in it and I agreed to it.
 I was at [St. Michael’s Hospital Addictions clinic] and the RN or the social worker there had brought it to my attention
 I was at my doctor’s and she said . . . there was a survey going on and because I used, I use and she said that she, she
thought that I would be a very good participant.
Compensation supports other
factors
 I wanted to do something with my family and help out others, the other half was the money . . . God witness I am a Christian
man I would have did it for free, I would have done it right then and there
 there was an opportunity right? . . . [I]t’s not about the reward either you know, because I, yeah, I do need the money, but it’s
more the educational part of it
Domain 2: study process experiences
Supportive environment  you’re very kind and, and very caring so, so that kind of leaves the door open to come back and, and just keep on with, with this
stuff
 I think you guys are very pleasant. I don’t think that you know, I don’t think you could approach somebody as nice you know,
you guys were great, very friendly, hmm, in, in that sense I don’ t, I don’t know if you could get any better you guys are you know,
so [Thank you] [yeah] I can’t think off the top of my head.
 the whole process so far from meeting you guys till now has been, you guys have been really great
Reminders  The reminder is good. I did not forget: [coffee shop] 9:30. . . . A friendly reminder right? I think that there’s no harm in that and
it will just raise the odds of you know, someone not forgetting so, keep doing it.
 . . . it reminded me because I was thinking that I didn’t realize it was today when you called yesterday.
Stigma  . . . when I came in the security was kind of looking at me like what’s this homeless girl . . . , like I just felt judgemental from
him. I said, “ is there a [coffee shop]?” At first he told me no. Then I pulled out your card and then . . . he’s like yeah, it’s, it’s
right there but you can wait over here so they can keep an eye on me and I said, “ no, I am going to go into [coffee shop] and I am
going to wait where you guys told me to wait.” I wasn’t going to say anything [Yeah] but then I was like no, no forget this I’m, I’m
going to talk to you guys and let you know.
Domain 3: simulation experiences
Benefit of hands-on
experiences
 I just think that everyone’s going to be different . . . It’s not something you can just read, you can read about it but until you
puts your hands in work and do it, it’s the only time you’re going to actually.
 just having this like hands on experience it definitely like makes you feel a lot more confident
Challenging and emotional
responses
 Honestly, because I just saved my friend I, I, I just pictured her.
 No, the manikin kind of freaked me out. I still think he’s breathing. Yeah, but he, he just looks weird.
 It’s challenging to set your mind and your body to a state where you can deal with it. . . . you have to really concentrate and,
and you know, try it again and again, which is unfortunate because there’s always someone’s life at stake. . . . it’s how you
practice it so, I, I just think that it’s a good thing that you guys do. . . . Knowledge, right, is power obviously and, and reading a
book and just reading the steps or, or you have to practice it?
Comfortable, affirming
environment
 I would say moderately comfortable before and, and absolutely comfortable now
 it’s comfortable, everything was comfortable, and it was professional
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candidates were not informed about the study. Despite our candidate-
driven recruitment methods, perceptions in the clinical environment
regarding individual risks of opioid overdose may introduce unmea-
sured selection biases.
The SOONER Trial is feasible and acceptable to study participants
and therefore ready for deployment.
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